Risks for UK Biotech (The Times)
John Rountree, Managing Partner of Novasecta, was recently quoted in the Sunday Times, the UK’s leading Sunday newspaper. In an article entitled “How to Make Our Scientists Very Mad” John offers commentary on the risks of Brexit to early-stage biotech companies, stating that the potential for decreased funding (from Horizon 2020, for example) may reduce the attractiveness […]
Novasecta’s Perspective on Brexit (Biotech and Money)
The UK’s recent Brexit referendum will have profound and likely negative consequences for the European economy. Globally-minded pharma companies have less to worry about than other less profitable industry sectors in which the companies are more reliant on the UK and/or Europe consumer economies alone. But all companies of all sectors will face economic headwinds. […]